Has Kevin Hogan received payments from drug or device companies?

Yes. Drug and device makers reported $1,811 in general payments to Kevin Hogan across 89 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kevin Hogan did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kevin Hogan come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kevin Hogan

Dermatology · Washington, DCNPI 1497730139

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Galderma Laboratories, L.p. at 30.5% of the total. That places this record below the midpoint for dermatology clinicians in DC, where the typical reported total is $3,159.

$1,811in general payments, 2019–2025

Across 89 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Galderma Laboratories, L.p.$553
Pfizer$159
AbbVie$131
Dermira, Inc.$129
Sanofi$117
Sun Pharmaceutical Industries Inc.$91
plus $631 from 13 others

What the payments were for

Food & beverage$1,811100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Galderma Laboratories, L.p.	29	$553
Pfizer	13	$159
AbbVie(2 entities)	4	$131
Dermira, Inc.	2	$129
Sanofi	3	$117
Sun Pharmaceutical Industries Inc.	5	$91
Biofrontera Inc.	6	$85
Johnson & Johnson	4	$72
Regeneron Healthcare Solutions, Inc.	2	$68
Novartis	3	$55
Lilly USA, LLC	3	$55
Ortho Dermatologics, A Division Of Bausch Health US, LLC	3	$53
Almirall LLC	3	$50
Mayne Pharma Commercial LLC	2	$49
LEO Pharma Inc.	2	$41
VYNE Pharmaceuticals Inc.	2	$40
Bristol Myers Squibb	1	$24
Janssen Scientific Affairs, LLC	1	$22
EPI Health, LLC	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

QBREXZA$105

How this compares

$1,811 in reported general payments places this provider in the 35th percentile of 73 dermatology providers in District of Columbia.

See all dermatology providers in District of Columbia →

Other dermatology in Washington

Jonathan SilverbergWashington$4.5M
Adam FriedmanWashington$2.2M
Terrence KeaneyWashington$1.1M
Candrice HeathWashington$168K
Agnes ChangWashington$109K
Todd PerkinsWashington$102K
Karl SaardiWashington$101K
Noelle SherberWashington$96K
Yolanda HolmesWashington$80K
Cheri FreyWashington$79K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →